BCM
BPMC

Bridgeway Capital Management’s Blueprint Medicines BPMC Stock Holding History

Bridgeway Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,600
Closed -$447K – 1338
2021
Q1 		$447K Buy
4,600
+1,200
+35% +$120K 0.01% 1113
2020
Q4 		$381K Buy
+3,400
New +$358K 0.01% 1046

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bridgeway Capital Management's BPMC Position: Q2 2021 in Review

Bridgeway Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 4,600 shares — an estimated $447K sold.

Bridgeway Capital Management first reported a position in BPMC in Q4 2020 and held it in 2 quarters. The position peaked at $447K in Q1 2021. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Bridgeway Capital Management reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Bridgeway Capital Management sold 4,600 Blueprint Medicines shares in Q2 2021, an estimated $447K.
  • Bridgeway Capital Management first reported a position in Blueprint Medicines in Q4 2020 and held it in 2 quarters.
  • Bridgeway Capital Management's Blueprint Medicines position peaked at $447K in Q1 2021.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Bridgeway Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.